The Boots Company Plc

Knoll Aktiengesellschaft

Basf Aktiengesellschaft

Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

David N Johnston

Bruce Jeremy Sargent

Lee Daniel Arnold

Paul Rafferty

James Edward Jeffery

Rainer Munschauer

John R Housley

Gavin C Hirst

David J Calderwood

Helen L Twigger

Andrew Philip Crew

Bernard John Armitage

Hormoz Mazdiyasni

David John Calderwood

Bojuan B Deng

Gerald B Tometzki

Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

4-aminopyrrolopyrimidines as kinase inhibitors

Pyrrolopyrimidines as therapeutic agents

Compounds of formula I ##STR1## including pharmaceutically acceptable salts thereof in which R.sub.1 represents hydrogen, 2-phenyl-1,3-dioxan-5-yl, a C.sub.1-6 alkyl group, a C.sub.3-8 cycloalkyl group, a C.sub.5-7 cycloalkenyl group or an (optionally substituted phenyl)C.sub.1-6 alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substituted by one or more groups of formula OR.sub.A in which R.sub.A represents H or a C.sub.1-6 alkyl group provided that a group of formula OR.sub.A is not located on the carbon attached to nitrogen;

Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors

Isoquinoline derivatives as therapeutic agents

Tetrahydroisoquinoline compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof, in which: R.sub.1 represents one or more substituents selected from H, halo, hydroxy, alkyl (optionally substituted by hydroxy), alkoxy, alkylthio, alkylsulphinyl, alkyl-sulphonyl, nitro, cyano, polyhaloalkyl, polyhaloalkoxy, phenyl (optionally substituted by one or more of halo, alkyl or alkoxy), or R.sub.1 is optionally alkylated carbamoyl;

Therapeutic agents

Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof; in which R.sub.1 and R.sub.2, which are the same or different, are H or an optionally substituted hydrocarbon group or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring;

Arylcyclobutylmethylamine therapeutic agents

Arylcyclobutylmethylamines

Compounds of formula I ##STR1## in which R.sub.1 is a heterocyclic ring containing one or more heteroatoms selected from N, O and S;

Antidepressant amines

Growing community of inventors

Nottingham, United Kingdom

David N Johnston